1Jemal A,Siegel R,Ward E,et al.Cancer statistics[J].CA Cancer J Clin,2007,57(1):43-66.
2Ganz PA.Survivorship:adult cancer survivors[J].Prim Care,2009,36(4):721-741.
3Adhami VM,Khan N,Mukhtar H.Cancer chemoprevention by pomegranate:laboratory and clinical evidence[J].Nutr Cancer,2009,61(6):811-815.
4Fiorentino M,Capizzi E,Loda M.Blood and tissue biomarkers in prostate cancer:,state of the art[J].Urol Clin North Am,2010,37(1):131-141.
5Finne P,Auvinen A,Mattanen L,et al.Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μ g per liter[J].Eur Urol,2008,54(2):362-370.
6Rubin MA,Bismar TA,Andren O,et al.Decreased alphamethylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death[J].Cancer Epidemiol Biomarkers Prev,2005,14(4):1424-1432.
7Paul B,Dhir R,Landsittel D,et al.Detection of prostate cancer with a blood-based assay for early prostatecancer antigen[J].Cancer Res,2005,65(10):4097-4106.
8Leman ES,Cannon GW,Track BJ,et al.EPCA-2:a highly specific serum marker for prostate cancer[J].Urology,2007,69(4):714-720.
9Jiang Z,Wu CL,Woda BA,et al.Alpha-methylacyl CoA racemase:a multi-institutional study of a new prostate cancer marker[J].Histopathology,2004,45(3):218-225.
10Nakada T,Noguchi Y,Satoh S,et al.NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer[J].Cancer Immun,2003,3(1):10-16.
8Reynolds M A,Kastury K,Groskopf J. Molecular markers for prostate cancer[J].CANCER LETTERS,2007,(01):5-13.
9Abrahamsson P A,Wadstrom L B,Alumets J. Peptide-hormone and serotonin-immunoreactive tumour cells in carcinoma of the prostate[J].Pathology - Research and Practice,1987,(03):298-307.
10Jemal A,Siegel R,Ward E. Cancer statistics,2008[J].CA: A Cancer Journal for Clinicians,2008,(02):71-96.
